• By Concept
  • By Last Name
  • By Full Text

Iwatsubo, Takeshi

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.



LEADERSHIP AND EXCELLENCE IN ALZHEIMERS DISEASE

Selkoe, Dennis J

1 August 1988 - 31 July 1995
NATIONAL INSTITUTE ON AGING
Total Funding: $ 5,792,330

FY 1994
5R35AG007911-07
$ 758,695
FY 1993
5R35AG007911-06
$ 769,936
FY 1992
5R35AG007911-05
$ 758,475
FY 1992
3R35AG007911-05S1
$ 91,000
FY 1991
5R35AG007911-04
$ 751,675
FY 1990
5R35AG007911-03
$ 856,248
FY 1989
5R35AG007911-02
$ 806,303
FY 1988
1R35AG007911-01
$ 999,998
 
 
$ 5,792,330
Abstract

This LEAD proposal will enable an interdisciplinary group of four investigators who have collaborated productively on macromolecular studies of Alzheimer's disease (AD) to expand their work into new aspects of the protein chemistry and molecular biology of regionally selective cellular dysfunction in AD brain. We will use biochemical, cell biological and molecular genetic techniques to elucidate further the complex age-related alterations of certain normal gene products (viz., the cytoskeletal protein, tau, and the precursor of the beta-amyloid protein (beta- AP) that invariably accompany progressive neuronal dysfunction in AD. Our experiments are based on specific hypotheses (described herein) about the origin of neuritic plaques and the reorganization of the neuronal cytoskeleton in AD. They seek answers to questions arising directly from recent progress in AD research. (1) How does the beta-AP precursor, whose gene is not known to be altered in AD and whose mRNAs are widely expressed in neural and non-neural tissues, undergo selective processing into amyloidogenic fragments only in certain brain regions, especially cortex and its microvasculature? (2) Whatever the mechanism of local amyloid formation, does the beta-AP itself (or associated macromolecules) exert any toxic and/or trophic effects on cortical cells, or is it inert? Can such effects be detected and studied in an in vitro or in vivo model? (3) In view of the widespread neuritic and perikaryal accumulation of altered, aggregated tau protein in AD, can we build on our recent progress in sequencing full-length cDNAs for both mouse and human tau to determine which epitopes of tau are deposited in AD, which kinases phosphorylate normal or AD tau at these epitopes and whether the critical microtubule binding domain is incorporated into PHF and thus dysfunctional in AD? Our experiments include: (a) detection of brain-region-specific fragments of the amyloid precursor that precede the formation of the final beta-AP subunit and a search for local proteases and their inhibitors that could effect this progressive processing; (b) a dynamic study of the assembly properties of fetal, adult and AD microtubule-associated proteins; and (c) analyses of the effects of beta-AP or adherent proteins on cortical neurons in vitro (humans) and in vivo (primates and rodents). We believe our new research program as well as our prior productivity and strong commitment to molecular research on AD will allow us to use the singular opportunities provided by the LEAD Award to full advantage.

34 Resulting Publications

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.

Related Grants

Related Publications